TY - JOUR
T1 - Appropriateness of empiric antibiotic therapy for community-acquired pneumonia
T2 - A multicenter cross-sectional study
AU - Rahme, Deema
AU - Chmaisse, Hania Nakkash
AU - Salameh, Pascale
N1 - Publisher Copyright:
© 2025 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC license. http://creativecommons.org/licenses/by-nc/4.0/
PY - 2025/12
Y1 - 2025/12
N2 - Background: Community-acquired pneumonia (CAP) remains a major public health concern, with appropriate empiric antibiotic therapy critical to improving patient outcomes and combating antimicrobial resistance (AMR). Despite the availability of national guidelines, adherence among physicians in Lebanon was previously unclear. Objective: To evaluate the appropriateness of empiric antibiotic prescribing for hospitalized CAP patients in Lebanon and identify factors associated with non-compliance with national guidelines. Methods: A cross-sectional study was conducted in five Lebanese hospitals across various regions. Medical records of 380 adult CAP patients were reviewed. Empiric antibiotic regimens were evaluated for compliance with national CAP guidelines based on drug selection, dosage, route, and duration. Multivariate logistic regression was used to identify predictors of inappropriate prescribing. Results: Only 38.9 % of patients received fully guideline-concordant empiric therapy. Inappropriate prescribing was significantly associated with physician rank (residents: aOR = 29.13, p = 0.001), geographic region (South Lebanon: aOR = 7.78, p = 0.028), and antibiotic class (β-lactam plus respiratory fluoroquinolones: aOR = 19.18, p < 0.001). Clinical factors such as systemic inflammatory response syndrome and elevated serum creatinine were also linked to inappropriate use. Conclusion: Non-compliance with national CAP treatment guidelines is widespread in Lebanese hospitals and driven by physician experience, geographic disparities, and misalignment in antibiotic selection. Strengthening antimicrobial stewardship programs, regional training, and clinical decision support is essential to improve adherence and reduce AMR risk.
AB - Background: Community-acquired pneumonia (CAP) remains a major public health concern, with appropriate empiric antibiotic therapy critical to improving patient outcomes and combating antimicrobial resistance (AMR). Despite the availability of national guidelines, adherence among physicians in Lebanon was previously unclear. Objective: To evaluate the appropriateness of empiric antibiotic prescribing for hospitalized CAP patients in Lebanon and identify factors associated with non-compliance with national guidelines. Methods: A cross-sectional study was conducted in five Lebanese hospitals across various regions. Medical records of 380 adult CAP patients were reviewed. Empiric antibiotic regimens were evaluated for compliance with national CAP guidelines based on drug selection, dosage, route, and duration. Multivariate logistic regression was used to identify predictors of inappropriate prescribing. Results: Only 38.9 % of patients received fully guideline-concordant empiric therapy. Inappropriate prescribing was significantly associated with physician rank (residents: aOR = 29.13, p = 0.001), geographic region (South Lebanon: aOR = 7.78, p = 0.028), and antibiotic class (β-lactam plus respiratory fluoroquinolones: aOR = 19.18, p < 0.001). Clinical factors such as systemic inflammatory response syndrome and elevated serum creatinine were also linked to inappropriate use. Conclusion: Non-compliance with national CAP treatment guidelines is widespread in Lebanese hospitals and driven by physician experience, geographic disparities, and misalignment in antibiotic selection. Strengthening antimicrobial stewardship programs, regional training, and clinical decision support is essential to improve adherence and reduce AMR risk.
KW - Antibiotic prescribing
KW - Antimicrobial resistance
KW - Community-acquired pneumonia
KW - Guideline adherence
KW - Lebanon
KW - Stewardship
UR - https://www.scopus.com/pages/publications/105024793550
U2 - 10.1016/j.rcsop.2025.100669
DO - 10.1016/j.rcsop.2025.100669
M3 - Article
AN - SCOPUS:105024793550
SN - 2667-2766
VL - 20
JO - Exploratory Research in Clinical and Social Pharmacy
JF - Exploratory Research in Clinical and Social Pharmacy
M1 - 100669
ER -